R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer IMUNON LHA Investor Relations David Gaiero Kim Sutton Golodetz 978-376-6352 212-838-3777 dgaiero@imunon.com kgolodetz@lhai.com Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark th ...